Диссертация (Получение и стандартизация биологически активных водорастворимых сополимеров на основе N-оксидов пиридина), страница 18

Castellino, J. Manischewitz, L.R. King, A. Honorkiewicz, M.T. Rock, K.M.Edwards, G. Del Giudice, R. Rappuoli, H. Golding // Sci. Transl. Med. – 2010. – V. 2. –P. 15- ra5.126112. Kieny, M.P. Research and development of new vaccines against infectiousdiseases / M.P. Kieny, J.L. Excler, M. Girard // Am J. Public Health. – 2004. – V.94. – P.1931-1935.113. Kimura, J. Studies on the adjuvant effect of water-in-oil-in-water emulsion insesame oil. I. Enhanced and persistent antibody formation by antigen incorporated intothe water-in-oil-in-water emulsion / J.Kimura, H.Nariuchi, T.Watanabe, T.Matuhasi,I.Okayasu, S.Hatakeyama // Jpn J Exp Med.

– 1978. – V. 48. – P.149–152.114. Klingsberg, E. Pyridine and Its Derivatives, part two. / E. Klingsberg. – NewJersey, 1961. – 583 р.115. Klinman, D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides /D.M. Klinman // Nat Rev Immunol. – 2004. – V. 4(4). – P.249–258.116. Kotani, S. Immunoadjuvant activities of cells walls, their water-solublefractions and peptidoglycan subunits, prepared from various gram-positive bacteria, andof synthetic N-acetylmuramyl peptides / S. Kotani, Y. Watanabe, T.

Shimoto, T. Narita,K. Kato, D.E.S. Stewart-Tull // Z Immunitatsforsch. – 1975. – V.149S. – P. 302–305.117. Krieg, A.M. CpG motifs in bacterial DNA and their immune effects / A.M.Krieg // Annu Rev Immunol. – 2002. – V. 20. – P.709–760.118. Krieg, A.M. Sequence motifs in adenoviral DNA block immune activation bystimulatory CpG motifs / A.M.Krieg, T.Wu, R.Weeratna, S.M.Efler, L.Love-Homan,L.Yang // Proc Natl Acad Sci USA.

– 1998. – V. 95(21). – P.12631–12636.119. Kundig, T.M. Der p 1 peptide on virus-like particles is safe and highlyimmunogenic in healthy adults / T.M.Kundig, G.Senti, G.Schnetzler, C.Wolf, B.M.PrinzVavricka, A.Fulurija // J Allergy Clin Immunol. – 2006. – V. 117. – P. 1470–1476.120. Laing, P.

The ’co-delivery’ approach to liposomal vaccines: application to thedevelopment of influenza-A and hepatitis-B vaccine candidates / P.Laing, A.Bacon,B.McCormack, G.Gregoriadis, B.Frisch, F.Schuber // J Liposome Res. – 2006. – V. 16.– P. 229–235.121. Leclerc, C. Synthetic immunomodulators and synthetic vaccines / C.Leclerc,F.Vogel // CRC Crit Rev Ther Drug Carrier Syst.

– 1986. – V. 2. – P. 353–357.127122. Lemaire, G. Natural and synthetic trehalose diesters as immunomodulators /G.Lemaire, J.P.Tenu, J.F.Petit, E.Lederer // Med Res Rev. – 1986. – V.6. – P. 243.123. Leroux-Roels, I. Priming with AS03 A-adjuvanted H5N1 influenza vaccineimproves the kinetics, magnitude and durability of the immune response after aheterologous booster vaccination: An open non-randomised extension of a doubleblindrandomised primary study / I.Leroux-Roels, F.Roman , S.Forgus, C.Maes, F.De Boever,M.Drame, P.Gillard, R.van der Most, M.Van Mechelen, E.Hanon, G.Leroux-Roels //Vaccine. – 2010. – V.28.

– P. 849- 857.124. Lobaina, Y. Immunological characterization of two hepatitis B core antigenvariants and their immunoenhancing effect on co-delivered hepatitis B surface antigen /Y.Lobaina, D.Palenzuela, D.Pichardo, V.Muzio, G.Guillen, J.C.Aguilar // Mol Immunol.– 2005. – V.

42. – P. 289–294.125. Lynch, J.M. Increased protection against pneumococcal disease by mucosaladministration of conjugate vaccine plus interleukin-12 / J.M.Lynch, D.E.Briles,D.W.Metzger // Infect Immun. – 2003. – V. 71. – P. 4780–4788.126. Malherbe, L. Vaccine adjuvants alter TCR-based selection thresholds /L.Malherbe, L.Mark, N.Fazilleau, L.J.McHeyzer-Williams, M.G.McHeyzerWilliams //Immunity. – 2008. – V. 28. – P. 698- 709.127. Marshall, J.D.

Superior activity of the type C class of ISS in vitro and in vivoacross multiple species / J.D.Marshall, K.L.Fearon, D.Higgins, E.M.Hessel, H.Kanzler,C.Abbate // DNA Cell Biol. – 2005. – V. 24. – P. 63–72.128. McCartney, S. Distinct and complementary functions of MDA5 and TLR3 inpoly (I:C)-mediated activation of mouse NK cells/ S. McCartney, W. Vermi, S. Gilfillan// J. Exp. Med. – 2009. – V.206. – P.2967 - 2976.129. McKee, A.S. How do adjuvants work? Important considerations for newgeneration adjuvants/ A.S. McKee, M.W.

Munks, P. Marrack // Immunity. – 2007. –V.27. – P.687 - 690.130. Nakamura, I. Copper-Catalyzed Tandem [2,3]-Rearrangement and 6π-3Azatriene Electrocyclization in (E)-O-Propargylic α,β-Unsaturated Oximes / I.Nakamura// JASC. – 2010. – Р.132128131. Ochiai, E. Recent Japanese Work on the Chemistry of Pyridine 1-Oxide andRelated Compounds / E.Ochiai – Tokyo. – 1952. P.

2–3.132. O'Hagan, D. T. Vaccine Adjuvants. Preparation Methods and ResearchProtocols / T. O'Hagan Derek // New Jersey: Humana Press Totowa, 2000. – 353 p.133. O’Hagan, D.T. The path to a successful vaccine adjuvant–«The long andwinding road» / D.T. O'Hagan, E. De Gregorio. // Drug Discov. Today.

– 2009. – V.14.– P. 541–551.134. O'Hagan, D.T. Recent developments in vaccine delivery systems, in NewGeneration Vaccines 2nd edn / D.T. O'Hagan, M.M. Kaper, J.B. Rappuoli // MarcelDekker. – 2004. – V.43. – P. 259-270.135. Parant, M.A. Immunostimulant activities of a lipophilic muramyl dipeptidederivative and of a desmuramyl peptidolipid analogue / M.A.Parant, F.M.Audibert,L.A.Chedid, M.R.Level, P.L.Lefrancier, J.P.Choay // Infect Immun. – 1980.

– V. 27. – P.826–830.136. Pearse, M.J. ISCOMATRIX adjuvant for antigen delivery / M.J.Pearse,D.Drane // Adv Drug Deliv Rev. – 2005. – V. 57. – P. 465–474.137. Petrovsky, N. Novel human polysaccharide adjuvants with dual Th1 and Th2potentiating activity / N.Petrovsky // Vaccine. – 2006. – V.24. – P. S2-26–S2-29.138.

Podda, A. The adjuvanted influenza vaccines with novel adjuvants:Experience with the MF59-adjuvanted vaccine / A. Podda // Vaccine. – 2001. – V. 19. –P. 2673–2680.139. Robinson, H.L. New hope for an AIDS vaccine / H.L.Robinson // Nat RevImmunol.

– 2002. – V.2. – P. 239–250.140. Rodrıguez, E.G. Enhanced cellmediated IFN-g-secreting activity against theHIV-1IIIB V3 peptide of the TAB9 multiepitope after DNA vaccine backboneengineering / E.G.Rodrıguez, D.M.Vazquez, A.M.Herrera, C.A.Duarte // BiochemBiophys Res Commun. – 2003. – V.308. – P. 713–718.141. Ronnberg, B. Adjuvant activity of non-toxic Quillaja saponaria Molinacomponents for use in iscom-matrix / B.

Ronnberg, M. Fekadu, B. Morein // Vaccine. –1995. – V. 13. – P. 1375– 1382.129142. Scheerlinck, J.P Systemic immune responses in sheep, induced by a novelnano-beadadjuvant/J.P.Scheerlinck,S.Gloster,A.Gamvrellis,P.L.Mottram,M.Plebanski // Vaccine. – 2006. – V.24. – P. 1124–1131.143. Schirmbeck, R. Antibody and cytotoxic T-cell responses to soluble hepatitisB virus (HBV) S antigen in mice: implications for the pathogenesis of HBV-inducedhepatitis // R. Schirmbeck, K. Melber, T.

Mertens, J. J. Reimann //Virol. – 1994. – V. 68.– P. 1418- 1425.144. Schwarz, T.F. Single dose vaccination with AS03-adjuvanted H5N1 vaccinesin a randomized trial induces strong and broad immune responsiveness to boostervaccination in adults. / T. Horacek, M. Knuf, H.G. Damman, F. Roman, M. Drame, P.Gillard, W. Jilg. // Vaccine. – 2009. – V.

27. – P. 6284- 6290.145. Shaker, Y. Recent trends in the chemistry of pyridine N-oxides / Y.Shaker //Arkivoc. 2001. – V.i. P. 242–268.146. Shaw, E.N. The Chemistry of Heterocyclic Compounds in Four Parts, PartTwo. Pyridine and Its Derivatives / E.N Shaw. – New York, 1961 – Р.147. Shek, P.N.

Comparison between multilamellar and unilamellar liposomes inenhancing antibody formation / P.N.Shek, B.Y.K.Yung, N.Z.Stanacev // Immunology. –1983. – V.49. – P.37–40.148. Skene, C.D. Saponin-adjuvanted particulate vaccines for clinical use /C.D.Skene, P.Sutton // Methods. – 2006.

– V. 40. – P. 53–59.149. Silva, D.G. Inulin-derived adjuvants efficiently promote both Th1 and Th2immune responses / D.G.Silva, P.D.Cooper, N.Petrovsky // Immunol Cell Biol. – 2004.– V.82. – P.611–666.150. Singh, M. Polylactide-co-glycolide microparticles with surface adsorbedantigens as vaccine delivery systems / M.Singh, J.Kazzaz, M.Ugozzoli, P.Malyala,J.Chesko, D.T.O’Hagan // Curr Drug Deliv. – 2006.

– V.3. – P.115–120.151. Smith, J.W.G. Response to influenza vaccine in adjuvant 65-4 / J.W.G.Smith,W.B.Fletcher, M.Peters, M.Westwood, F.T. Perkins // J Hyg (Camb). – 1975. – V.74. –P.251–255.130152. Storni, T. Immunity in response to particulate antigen-delivery systems /T.Storni, T.M.Kundig, G.Senti, P.Johansen // Adv Drug Deliv Rev. – 2005. – V.57. –P.333–355.153. Straw, B.E. Comparison of tissue reactions produced by Haemophiluspleuropneumoniae vaccines made with six different adjuvants in swine / B.E.Straw, N.J.MacLachlan, W.T. Corbett, P.B. Carter, Schey H.M. // Can J Comp Med.

– 1985. – V.49. – P. 149- 151.154. Sullivan, S.P. Dissolving polymer microneedle patches for influenzavaccination / S. P. Sullivan, D. G. Koutsonanos, M. del P. Martin, J. W. Lee, V. Zarnitsyn,S.Choi, N. Murthy, R.W. Compans, I. Skountzou, M. R. Prausnitz // Nature medicine.

–2010. – V. 16. – №. 8. – p. 915-920.155. Tafaghodi, M. Nasal immunization studies using liposomes loaded withtetanus toxoid and CpG-ODN / M.Tafaghodi, M.R.Jaafari, S.A.Sajadi-Tabassi // Eur JPharm Biopharm. – 2006. – V.64. – 138–145.156. Takahashi, H. Induction of CD8+ cytotoxic T cells by immunization withpurified HIV-1 envelope protein in ISCOMs / H.Takahashi, T. Takeshita, B.

Morein, S.Putney, R.N. Germain, J.A.Berzofsky // Nature. – 1990.– V. 344. – P.873 - 875.157. Taneichi, M. Antigen chemically coupled to the surface of liposomes arecrosspresented to CD8+ T cells and induce potent antitumor immunity / M.Taneichi,H.Ishida, K.Kajino, K.Ogasawara, Y.Tanaka, M.Kasai // J Immunol.

– 2006. – V.177. –2324–2330.158. Taylor, P.J. Antibody response and reactions to aqueous influenza vaccine,simple emulsion vaccine and multiple emulsion vaccine / P.J.Taylor, C.L.Miller,T.M.Pollock, F.T.Perkins, M.A.Westwood // J Hyg (Camb). – 1969.

– V.67. – P.485–490.159. Thomas, L. Gilchrist A new route to 3-alkoxypyridine 1-oxides / L.Thomas,M.George // J. Chem. Soc. Chem. Commun. – 1981. Р. 696–698.160. Tokunaga, T. Antitumor activity of deoxyribonucleic acid fraction fromMycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor131activity / T.Tokunaga, H.Yamamoto, S.Shimada, H.Abe, T.Fukuda, Y.Fujisawa // J NatlCancer Inst. – 1984. – V.72. – P.955–962.161.

Tomai, M.A. T cell and interferon-gamma involvement in the adjuvant actionof a detoxified endotoxin / M.A.Tomai, A.G.Johnson // J Biol Resp Modifiers. – 1989. –V. 8. – P.625–630.162. Tong, N.K. Immunogenicity and safety of an adjuvanted hepatitis B vaccinein pre-hemodialysis and hemodialysis patients / N.K.Tong, J.Beran, S.A.Kee, J.L.Miguel,C.Sanchez, J.M.Bayas // Kidney Int. – 2005. – V.